Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A treatment strategy for KRAS-driven tumors.

Literature DB >> 29988139

A treatment strategy for KRAS-driven tumors.

Trang T Mai¹, Piro Lito^2,3.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2018 PMID： 29988139 DOI： 10.1038/s41591-018-0111-x

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

Review 1. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

Authors: Ritu R Singh; Johanna Goldberg; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly
Journal: Cancer Treat Rev Date: 2019-03-22 Impact factor: 12.111

Review 2. The role of the glutamine transporter ASCT2 in antineoplastic therapy.

Authors: Estefânia Teixeira; Cláudia Silva; Fátima Martel
Journal: Cancer Chemother Pharmacol Date: 2021-01-19 Impact factor: 3.333

Review 3. RAF kinase dimerization: implications for drug discovery and clinical outcomes.

Authors: Tilman Brummer; Campbell McInnes
Journal: Oncogene Date: 2020-04-08 Impact factor: 9.867

4. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

Authors: Marco H Hofmann; Michael Gmachl; Juergen Ramharter; Fabio Savarese; Daniel Gerlach; Joseph R Marszalek; Michael P Sanderson; Dirk Kessler; Francesca Trapani; Heribert Arnhof; Klaus Rumpel; Dana-Adriana Botesteanu; Peter Ettmayer; Thomas Gerstberger; Christiane Kofink; Tobias Wunberg; Andreas Zoephel; Szu-Chin Fu; Jessica L Teh; Jark Böttcher; Nikolai Pototschnig; Franziska Schachinger; Katharina Schipany; Simone Lieb; Christopher P Vellano; Jonathan C O'Connell; Rachel L Mendes; Jurgen Moll; Mark Petronczki; Timothy P Heffernan; Mark Pearson; Darryl B McConnell; Norbert Kraut
Journal: Cancer Discov Date: 2020-08-19 Impact factor: 39.397

A treatment strategy for KRAS-driven tumors.

Review 1. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

Review 2. The role of the glutamine transporter ASCT2 in antineoplastic therapy.

Review 3. RAF kinase dimerization: implications for drug discovery and clinical outcomes.

4. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

5. TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer.

6. A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma.

Review 7. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.

Review 8. The path to the clinic: a comprehensive review on direct KRAS^G12C inhibitors.

A treatment strategy for KRAS-driven tumors.

Review 1. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

Review 2. The role of the glutamine transporter ASCT2 in antineoplastic therapy.

Review 3. RAF kinase dimerization: implications for drug discovery and clinical outcomes.

4. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

5. TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer.

6. A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma.

Review 7. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.

Review 8. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.

Review 8. The path to the clinic: a comprehensive review on direct KRAS^G12C inhibitors.